Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2007
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.
Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 59 citations in OpenAlex.
- Sublingual Fast-Dissolving Thin Films of Loratadine: Characterization, In Vitro and Ex Vivo Evaluation.Polymers · 2024Article
- Clinical Efficacy of Allergen-Specific Immunotherapy from Patient and Physician Perspectives.Yonsei medical journal · 2019Article
- GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization.Human vaccines & immunotherapeutics · 2019Article
- Sublingual allergen immunotherapy for respiratory allergy: a systematic review.Drugs in context · 2018Article
- Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study.Drugs - real world outcomes · 2017Article
- Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain.Drugs in context · 2017Article
- Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain.Clinical and molecular allergy : CMA · 2017Article
- Importance of Quality of Life for Adherence to Sublingual Immunotherapy.BioMed research international · 2016Article
- Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis.Drug design, development and therapy · 2015Review
- Allergen immunotherapy: routes, safety, efficacy, and mode of action.ImmunoTargets and therapy · 2013Review
- Sub-lingual immunotherapy: world allergy organization position paper 2009.The World Allergy Organization journal · 2009Article
- Allergic rhinoconjunctivitis: complementary treatments for the 21st century.Current allergy and asthma reports · 2009Review
- Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax®.Therapeutics and clinical risk management · 2008Article
- Impact of nickel oral hyposensitization on quality of life in systemic nickel allergy syndrome.International journal of immunopathology and pharmacologyObservational
- Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of sublingual immunotherapy on quality of life (QoL) was examined in patients with grass pollen-induced rhinoconjunctivitis. Patients (n = 855) were randomised to once-daily grass allergen tablets (2,500; 25,000; or 75,000 SQ-T Phleum pratense extract; GRAZAX or placebo. Treatment was initiated 8 weeks before the start of the grass pollen season and continued throughout. If symptoms were present, patients received loratadine or placebo rescue medication. There were three major findings: in patients using loratadine, grass allergen tablets provided QOL benefits over placebo; Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score was 17% (p = 0.006) and 20% (p = 0.020) greater with 75,000 SQ-T tablet than with placebo at first and second seasonal visit, respectively; in patients not using loratadine, grass allergen tablets improved QoL more than placebo; RQLQ score was 21% greater (p = 0.021) with 75,000 SQ-T tablet at second seasonal visit; grass tablets (without loratadine) had a greater effect on QoL than loratadine alone. RQLQ score was 26% (p = 0.014) greater with 75,000 SQ-T tablets than loratadine at second seasonal visit. These data show that sublingual immunotherapy with grass allergen tablets improves QOL in allergic rhinoconjunctivitis, reduces symptoms, and that this effect is greater than rescue antihistamine alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.